Autopsy report · NCT04466917

A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

“Sponsor decision to early terminate the study”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Amgen

Sponsor type

Industry

Conditions

Metastatic Non-small Cell Lung Cancer (NSCLC); Non-squamous NSCLC

Interventions

ABP 215; Bevacizumab; Paclitaxel; Carboplatin

Participants

0

Trials that died the same way

• Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
  “Sponsor decision to terminate the study” (96% match in meaning)
• An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
  “The sponsor decided to terminate the study early” (95% match in meaning)
• Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
  “Sponsor decided to terminate study early” (93% match in meaning)
• Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
  “Sponsor decision to terminate study.” (93% match in meaning)
• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.